Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemiaDaniele Caracciolo, Pierfrancesco Tassone, Chiara Buracchi et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 26
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Valter Gattei, Fortunato Morabito et al.|Leukemia|2020Cited by 24
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|American Journal of Hematology|2021Cited by 14
Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)Cirino Botta, Pierfrancesco Tassone, Giuseppe Gaipa et al.|Blood|2018Cited by 1
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and RituximabMassimo Gentile, Fortunato Morabito, Gianluigi Reda et al.|Blood|2019Cited by 1